Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 300, Issue 3, 2011, Pages

  Pankey, Edward A ^a   Bhartiya Jr , Manish ^a   Badejo Jr , Adeleke M ^a   Haider, Umair ^a   Stasch, Johannes Peter ^b   Murthy, Subramanyam N ^a   Nossaman, Bobby D ^a,c   Kadowitz, Philip J ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

^c BAYER AG   (Germany)

Author keywords

1H 1,2,4 oxadizaolo 4,3 quinoxaline 1 one; 2 1 2 (fluorophenyl)methyl 1Hpyrazolo 3,4 b pyridin 3 yl 5(4 morpholinyl) 4,6 pyrimidinediamine; 4 ( (4 carboxybutyl) 2 (5 fluoro 2 4' (trifluoromethyl)biphenyl 4 yl methoxy phenyl) ethyl amino methyl)benzoic acid; Guanylyl cyclase activator stimulator inhibitor; Monocrotaline; Nw nitro L arginine methyl ester hydrochloride; Nitric oxide synthase donor; Pulmonary and systemic vascular beds; Pulmonary hypertension; Sodium nitroprusside; U 46619

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 1H [1,2,4] OXADIZAOLO[4,3]QUINOXALINE 1 ONE; 4 [[(4 CARBOXYBUTYL)[2 [5 FLUORO 2 [[4' (TRIFLUOROMETHYL)BIPHENYL 4 YL]METHOXY]PHENYL]ETHYL]AMINO]METHYL]BENZOIC ACID; [1 [2 (FLUOROPHENYL)METHYL] 1H PYRAZOLO(3,4 B)PYRIDIN 3 YL] 5(4 MORPHOLINYL) 4,6 PYRIMIDINEDIAMINE; BAY 41 8543 2; BAY 60 2770; ENZYME INHIBITOR; GUANYLATE CYCLASE ACTIVATOR; HEME; MONOCROTALINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; THROMBOXANE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL; DRUG INFUSION; DRUG RESPONSE; ENZYME ACTIVITY; HEART OUTPUT; IN VIVO STUDY; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; BENZOIC ACIDS; GUANYLATE CYCLASE; HEME; HYDROCARBONS, FLUORINATED; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE; OXADIAZOLES; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 79955075916     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00953.2010     Document Type: Article

References (30)

1. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 74: 3203-3207, 1977.
2. Badejo AM Jr, Nossaman VE, Pankey EA, Bhartiya M, Kannadka CB, Murthy SN, Nossaman BD, Kadowitz PJ. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, Bay 41-8543, are modulated by nitric oxide. Am J Physiol Heart Circ Physiol 299: H1153-H1159, 2010.
3. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 49: 1128-1133, 2007.
4. Boulton CL, Southam E, Garthwaite J. Nitric oxide-dependent longterm potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase. Neuroscience 69: 699-703, 1995.
5. Braughler JM, Mittal CK, Murad F. Effects of thiols, sugars, and proteins on nitric oxide activation of guanylate cyclase. J Biol Chem 254: 12450-12454, 1979.
6. Chester M, Tourneux P, Seedorf G, Grover TR, Gien J, Abman SH. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 297: L318-L325, 2009.
7. Craven PA, DeRubertis FR. Requirement for heme in the activation of purified guanylate cyclase by nitric oxide. Biochim Biophys Acta 745: 310-321, 1983.
8. Edwards JC, Ignarro LJ, Hyman AL, Kadowitz PJ. Relaxation of intrapulmonary artery and vein by nitrogen oxide-containing vasodilators and cyclic GMP. J Pharmacol Exp Ther 228: 33-42, 1984.
9. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48: 184-188, 1995.
10. Homer KL, Fiore SA, Wanstall JC. Inhibition by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of responses to nitric oxide-donors in rat pulmonary artery: influence of the mechanism of nitric oxide generation. J Pharm Pharmacol 51: 135-139, 1999.
11. Ignarro LJ, Byrns RE, Buga GM, Wood KS. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ Res 61: 866-879, 1987.
12. Ignarro LJ, Degnan JN, Baricos WH, Kadowitz PJ, Wolin MS. Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta 718: 49-59, 1982.
13. Knorr A, Hirth-Dietrich C, Alonso-Alija C, Harter M, Hahn M, Keim Y, Wunder F, Stasch JP. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 58: 71-80, 2008.
14. Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J, Mueck W, Unger S, Wensing G, Frey R. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 119: 2781-2788, 2009.
15. Mueck W, Frey R. Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure. Clin Pharmacokinet 49: 119-129, 2010.
16. Radovits T, Korkmaz S, Miesel-Groschel C, Seidel B, Stasch JP, Merkely B, Karck M, Szabo G. Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. Eur J Cardiothorac Surg In press.
17. Schmidt HH, Schmidt PM, Stasch JP. NO-and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 191: 309-339, 2009.
18. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, Perzborn E, Schramm M, Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 135: 333-343, 2002.
19. Stasch JP, Dembowsky K, Perzborn E, Stahl E, Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 135: 344-355, 2002.
20. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F. NO-and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136: 773-783, 2002.
21. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Kumar HS, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, Schmidt HH. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552-2561, 2006.
22. Stone JR, Marletta MA. Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry 33: 5636-5640, 1994.
23. Stone JR, Marletta MA. Spectral and kinetic studies on the activation of soluble guanylate cyclase by nitric oxide. Biochemistry 35: 1093-1099, 1996.
24. Tseng CM, Tabrizi-Fard MA, Fung HL. Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation. J Pharmacol Exp Ther 292: 737-742, 2000.
25. Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, Changsirivathanathamrong D, Wu BJ, Ball HJ, Thomas SR, Kapoor V, Celermajer DS, Mellor AL, Keaney JF Jr, Hunt NH, Stocker R. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med 16: 279-285, 2010.
26. Wedel B, Humbert P, Harteneck C, Foerster J, Malkewitz J, Bohme E, Schultz G, Koesling D. Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proc Natl Acad Sci USA 91: 2592-2596, 1994.
27. Weissmann N, Hackemack S, Dahal BK, Pullamsetti SS, Savai R, Mittal M, Fuchs B, Medebach T, Dumitrascu R, Eickels M, Ghofrani HA, Seeger W, Grimminger F, Schermuly RT. The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 297: L658-L665, 2009.
28. Zhao Y, Brandish PE, Ballou DP, Marletta MA. A molecular basis for nitric oxide sensing by soluble guanylate cyclase. Proc Natl Acad Sci USA 96: 14753-14758, 1999.
29. Zhao Y, Brandish PE, DiValentin M, Schelvis JP, Babcock GT, Marletta MA. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 39: 10848-10854, 2000.
30. Zhou Z, Pyriochou A, Kotanidou A, Dalkas G, van Eickels M, Spyroulias G, Roussos C, Papapetropoulos A. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol 295: H1763-H1771, 2008.